Trial for advanced liver cancer using ABSK-011 plus atezolizumab
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18+) who can understand and sign informed consent, and follow study visits and procedures.
- You have confirmed advanced or unresectable liver cancer (HCC) that cannot be cured with surgery or local treatments.
- Your liver function score (Child-Pugh) must be 5 or 6, and you should not have serious complications like confusion from liver disease (hepatic encephalopathy) or fluid buildup (ascites) needing treatment within 7 days before starting.
- You need tumor tissue available: either an archived sample from past tests or you can have a new biopsy for required testing (FGF19 overexpression).
- Your cancer stage must be B or C (BCLC stage), and you must have at least one measurable tumor spot on scans.
- You must not have had major recent brain/spinal spread, and you must meet other safety rules like no autoimmune disease history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.